Skip to Content
Merck
CN

Z-004

Zaleplon solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C17H15N5O
CAS Number:
151319-34-5
Molecular Weight:
305.33
NACRES:
NA.24
UNSPSC Code:
41116107
EC Number:
200-659-6

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI key

HUNXMJYCHXQEGX-UHFFFAOYSA-N

InChI

1S/C17H15N5O/c1-3-21(12(2)23)15-6-4-5-13(9-15)16-7-8-19-17-14(10-18)11-20-22(16)17/h4-9,11H,3H2,1-2H3

SMILES string

CCN(C(C)=O)c1cccc(c1)-c2ccnc3c(cnn23)C#N

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable, liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

Quality Level

300

Gene Information

human ... GABRA1(2554), GABRB1(2560), GABRG2(2566)

Related Categories

General description

Zaleplon is a nonbenzodiazepine “Z-drug” prescribed under the trade names Sonata® or Starnoc for the treatment of insomnia. Zaleplon is often abused illicitly for its mind-altering effects. This Certified Spiking Solution® is applicable to use in LC/MS or GC/MS applications for urine drug testing, clinical toxicology, and forensic analysis.

Legal Information

Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Sonata is a registered trademark of King Pharmaceuticals Research and Development, Inc.
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes

Storage Class

3 - Flammable liquids

wgk

WGK 1

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup

Regulatory Information

监管及禁止进口产品
This item has

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Monique A J Mets et al.
Sleep medicine reviews, 14(4), 259-267 (2010-02-23)
Disturbed body balance and standing steadiness are problematic for those who wake up at night or in the morning after using hypnotic drugs. As a result, falls and hip fractures are frequently reported in patients using sleep medication. A literature
Charles B Schaffer et al.
Journal of affective disorders, 128(3), 305-308 (2010-08-13)
Insomnia in patients with bipolar disorder (BD) can cause distress, daytime dysfunction, cognitive impairment, worsening of hypomanic/manic symptoms and increased suicide risk. Physicians often prescribe hypnotics for BD patients with insomnia although no hypnotic has a specific FDA indication for
Adam R Lancaster et al.
Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001), 21(6), 658-665 (2012-02-10)
To summarize the signalment, clinical signs observed, time to onset of clinical signs, duration of clinical signs, and the outcome in a large case series of nonbenzodiazepine sleep aid ingestions in dogs, including 2 sleep aids that have not been
David J Greenblatt et al.
Biopharmaceutics & drug disposition, 32(9), 489-497 (2011-09-22)
Two investigations aimed to define the pharmacokinetic profile of a modified-release preparation of zaleplon (SKP-1041). Protocol SOM001 was a 5-way crossover, double-blind, randomized trial comparing three novel modified-release formulations of zaleplon 15 mg (SKP-1041A, SKP-1041B, SKP-1041C) to placebo and immediate-release
Karthik Y Janga et al.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 80(2), 347-357 (2011-11-02)
The present systematic study focused to investigate the combined advantage of proliposomes and surface charge for improved oral delivery of zaleplon. The zaleplon loaded proliposomes were prepared using hydrogenated soyphosphatidylcholine (HSPC) and cholesterol (CHOL) in varying ratios, and the optimized
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service